Commercial/Healthcare Exchange PA Criteria
Effective: September 14, 2021

Prior Authorization: Rezurock

Products Affected: Rezurock (belumosudil) tablets

Medication Description:
Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (ROCK) which inhibits ROCK2 and ROCK1. Belumosudil down-regulated proinflammatory responses via regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in ex-vivo or in vitro-human T cell assays. Belumosudil also inhibited aberrant pro-fibrotic signaling, in vitro. In vivo, belumosudil demonstrated activity in animal models of chronic GVHD.

Covered Uses:
Treatment of chronic graft-versus-host disease (chronic GVHD)

Exclusion Criteria: N/A

Required Medical Information:
1. Diagnosis
2. Previous medications tried and failed

Age Restrictions: 12 years of age and older

Prescriber Restrictions: None

Coverage Duration: 12 months

Other Criteria:

I. Initial Approval Criteria

1.Graft-versus-host disease, chronic
Patient must meet all the below criteria:
A. Patient has a diagnosis of chronic graft-versus-host disease (chronic GVHD); AND
B. Patient has tried and failed at least 2 prior lines of systemic therapy.

II. Continued Therapy

1. Graft-versus-host disease, chronic
A. Member has responded positively to the treatment as determined by the prescribing physician; AND
B. Member has not experienced unacceptable toxicity from the drug.

Quantity Limit:
30 tablets for 30 days
*60 tablets for 30 days, if used in combination with strong CYP3A inducers or Proton Pump Inhibitors

References:

1. Rezurock [package insert]. Warrendale, PA. Kadmon Pharmaceuticals, LLC. Updated July 16, 2021. Accessed August 9, 2021.
2. Rezurock. IBM Micromedex® [database online]. Greenwood Village, CO. Truven Health Analytics. Available at: https://www.micromedexsolutions.com. Updated July 22, 2021. Accessed August 9, 2021.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	9/14/2021
2	Update	Updated QL to allow approval for twice daily dosing if used in combination with strong CYP3A inducers or Proton Pump Inhibitors	Quantity Limits	12/16/2021